Clinical Pearls for Community Oncologists Treating Relapsed/Refractory AML
Ghayas C. Issa, MD, offers closing thoughts on genetic testing and targeted therapies for patients with relapsed/refractory acute myeloid leukemia.
Ongoing Research and Future Perspectives in Relapsed/Refractory AML
Clinical insights on the evolving treatment landscape for patients with relapsed/refractory acute myeloid leukemia, with a focus on ongoing research and unmet needs.
Recent Data in Relapsed/Refractory Acute Myeloid Leukemia
A medical oncologist reviews clinical trial data for revumenib and ziftomenib for patients with relapsed/refractory acute myeloid leukemia.
The Role of KMT2Ar/NPM1 and Menin in Relapsed/Refractory AML
Ghayas C. Issa, MD, discusses the pathway between KMT2A rearrangements/NPM1 and menin in relation to leukemia cells and how these genetic abnormalities impact prognosis.
Acute Myeloid Leukemia Subtypes and Risk Stratification
An expert on acute myeloid leukemia gives an overview of disease subtypes and provides insights on risk stratification.
Acute Myeloid Leukemia: Patient Presentation and Evaluating Response
Ghayas C. Issa, MD, describes the typical presentation of patients with acute myeloid leukemia and provides clinical insights on evaluating response and potential disease progression.